Journal Mobile Options
Table of Contents
Vol. 35, No. 1-2, 2013
Issue release date: February 2013
Dement Geriatr Cogn Disord 2013;35:106–117

Neuroimaging and Biochemical Markers in the Three Variants of Primary Progressive Aphasia

Gil-Navarro S. · Lladó A. · Rami L. · Castellví M. · Bosch B. · Bargalló N. · Lomeña F. · Reñé R. · Montagut N. · Antonell A. · Molinuevo J.L. · Sánchez-Valle R.
aAlzheimer’s Disease and Other Cognitive Disorders Unit, Department of Neurology, and Departments of bRadiology and cNuclear Medicine, Hospital Clínic, and dInstitut d’Investigació Biomédica August Pi I Sunyer (IDIBAPS), Barcelona, and eDepartment of Neurology, Hospital Universitario de Bellvitge, L’Hospitalet de Llobregat, Spain

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background/Aim: To investigate in variants of primary progressive aphasia (PPA) the association between current clinical and neuroimaging criteria and biochemical/genetic markers at the individual level. Methods: Thirty-two PPA patients were classified as non-fluent/agrammatic (nfvPPA), semantic (svPPA), or logopenic variant (lvPPA) or as unclassifiable (uPPA). In all patients, we evaluated the neuroimaging criteria (magnetic resonance imaging and/or single photon emission computed tomography/positron emission tomography) of each variant and studied serum progranulin levels, APOE genotype and Alzheimer’s disease (AD)-cerebrospinal fluid (CSF) biomarkers. Cases with a first-degree family history of early-onset dementia were genetically tested. Results: Ten of 15 (66%) nfvPPA, 5/5 (100%) svPPA and 7/7 (100%) lvPPA patients showed at least one positive neuroimaging-supported diagnostic criterion. All lvPPA and 3/5 (60%) uPPA patients presented AD-CSF biomarkers, which were absent in nfvPPA and svPPA cases. Four (27%) nfvPPA patients had dementia-causing mutations: 2 carried a GRN mutation and 2 the C9ORF72 hexanucleotide expansion. Conclusions: There was an excellent association between clinical criteria and neuroimaging-supported biomarkers in svPPA and lvPPA, as well as with AD-CSF biochemical markers in the lvPPA. Neuroimaging, biochemical and genetic findings in nfvPPA were heterogeneous. Incorporating biochemical/genetic markers into the PPA clinical diagnosis would allow clinicians to improve their predictions of PPA neuropathology, especially in nfvPPA and uPPA cases.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Mesulam MM: Primary progressive aphasia. Ann Neurol 2001;49:425–432.
  2. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF, Manes F, Dronkers NF, Vandenberghe R, Rascovsky K, Patterson K, Miller BL, Knopman DS, Hodges JR, Mesulam MM, Grossman M: Classification of primary progressive aphasia and its variants. Neurology 2011;76:1006–1014.
  3. Grossman M: The non-fluent/agrammatic variant of primary progressive aphasia. Lancet Neurol 2012;11:545–555.
  4. Ogar JM, Dronkers NF, Brambati SM, Miller BL, Gorno-Tempini ML: Progressive nonfluent aphasia and its characteristic motor speech deficits. Alzheimer Dis Assoc Disord 2007;21:S23–S30.
  5. Hodges JR, Patterson K, Oxbury S, Funnell E: Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. Brain 1992;115:1783–1806.
  6. Gorno-Tempini ML, Dronkers NF, Rankin KP, Ogar JM, La Phengrasamy BA, Rosen HJ, Johnson JK, Weiner MW, Miller BL: Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 2004;55:335–346.
  7. Leyton CE, Villemagne VL, Savage S, Pike KE, Ballard KJ, Piguet O, Burrell JR, Rowe CC, Hodges JR: Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using beta-amyloid imaging. Brain 2011;134:3030–3043.
  8. Rabinovici GD, Jagust WJ, Furst AJ, Ogar JM, Racine CA, Mormino EC, O’Neil JP, Lal RA, Dronkers NF, Miller BL, Gorno-Tempini ML: Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 2008;64:388–401.
  9. Snowden J, Neary D, Mann D: Frontotemporal lobar degeneration: clinical and pathological relationships. Acta Neuropathol 2007;114:31–38.
  10. Mesulam M, Wicklund A, Johnson N, Rogalski E, Léger GC, Rademaker A, Weintraub S, Bigio EH: Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol 2008;63:709–719.
  11. Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG: The evolution and pathology of frontotemporal dementia. Brain 2005;128:1996–2005.
  12. Josephs KA, Duffy JR, Strand EA, Whitwell JL, Layton KF, Parisi JE, Hauser MF, Witte RJ, Boeve BF, Knopman DS, Dickson DW, Jack CR Jr, Petersen RC: Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 2006;129:1385–1398.
  13. Knibb JA, Xuereb JH, Patterson K, Hodges JR: Clinical and pathological characterization of progressive aphasia. Ann Neurol 2006;59:156–165.
  14. Snowden JS, Rollinson S, Thompson JC, Harris JM, Stopford CL, Richardson AM, Jones M, Gerhard A, Davidson YS, Robinson A, Gibbons L, Hu Q, DuPlessis D, Neary D, Mann DM, Pickering-Brown SM: Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain 2012;135:693–708.
  15. Mahoney CJ, Beck J, Rohrer JD, Lashley T, Mok K, Shakespeare T, Yeatman T, Warrington EK, Schott JM, Fox NC, Rossor MN, Hardy J, Collinge J, Revesz T, Mead S, Warren JD: Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain 2012;135:736–750.
  16. Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, Van Kamp GJ, Van Swieten JC, Scheltens P: Amyloid beta(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 2004;62:1580–1584.
  17. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC,Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B: Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306–319.
  18. Herholz K, Ebmeier K: Clinical amyloid imaging in Alzheimer’s disease. Lancet Neurol 2011;10:667–670.
  19. Rohrer JD, Ridgway GR, Crutch SJ, Hailstone J, Goll JC, Clarkson MJ, Mead S, Beck J, Mummery C, Ourselin S, Warrington EK, Rossor MN, Warren JD: Progressive logopenic/phonological aphasia: erosion of the language network. Neuroimage 2010;49:984–933.
  20. Rohrer JD, Rossor MN, Warren JD: Alzheimer’s pathology in primary progressive aphasia. Neurobiol Aging 2012;33:744–752.
  21. Rami L, Gómez-Ansón B, Sánchez-Valle R, Bosch B, Monte GC, Lladó A, Molinuevo JL: Longitudinal study of amnestic patients at high risk for Alzheimer’s disease: clinical, neuropsychological and magnetic resonance spectroscopy features. Dement Geriatr Cogn Disord 2007;24:402–410.
  22. Goodglass H, Kaplan E: The Assessment of Aphasia and Related Disorders, ed 2. Philadelphia, Lea and Febiger, 1983.
  23. Kaplan E, Goodglass H, Weintraub S: Boston Naming Test. Philadelphia, Lea and Febiger, 1983.
  24. Borkowski JG, Benton AL, Speen O: Word fluency and brain damage. Neuropsychologia 1967;5:135–140.

    External Resources

  25. Howard D, Patterson K: Pyramids and Palm Trees: A Test of Semantic Access from Pictures and Words. Bury St Edmunds, Thames Valley Publishing Company, 1992.
  26. Antonell A, Gil S, Sanchez-Valle R, Balasa M, Bosch B, Prat MC, Chiollaz AC, Fernández M, Yagüe J, Molinuevo JL, Lladó A: Serum progranulin levels in patients with frontotemporal lobar degeneration and Alzheimer’s disease: detection of GRN mutations in a Spanish cohort. J Alzheimers Dis 2012;31:581–591.

    External Resources

  27. Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, Kalimo H, Paetau A, Abramzon Y, Remes AM, Kaganovich A, Scholz SW, Duckworth J, Ding J, Harmer DW, Hernandez DG, Johnson JO, Mok K, Ryten M, Trabzuni D, Guerreiro RJ, Orrell RW, Neal J, Murray A, Pearson J, Jansen IE, Sondervan D, Seelaar H, Blake D, Young K, Halliwell N, Callister JB, Toulson G, Richardson A, Gerhard A, Snowden J, Mann D, Neary D, Nalls MA, Peuralinna T, Jansson L, Isoviita VM, Kaivorinne AL, Hölttä-Vuori M, Ikonen E, Sulkava R, Benatar M, Wuu J, Chiò A, Restagno G, Borghero G, Sabatelli M, ITALSGEN Consortium, Heckerman D, Rogaeva E, Zinman L, Rothstein JD, Sendtner M, Drepper C, Eichler EE, Alkan C,Abdullaev Z, Pack SD, Dutra A, Pak E, Hardy J, Singleton A, Williams NM, Heutink P, Pickering-Brown S, Morris HR, Tienari PJ, Traynor BJ: A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257–268.
  28. Antonell A, Fortea J, Rami L, Bosch B, Balasa M, Sánchez-Valle R, Iranzo A, Molinuevo JL, Lladó A: Different profiles of Alzheimer’s disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. J Neural Transm 2011;118:259–262.
  29. Welge V, Fiege O, Lewczuk P, Mollenhauer B, Esselmann H, Klafki HW, Wolf S, Trenkwalder C, Otto M, Kornhuber J, Wiltfang J, Bibl M: Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer’s disease. J Neural Transm 2009;116:203–212.
  30. Rohrer JD, Knight WD, Warren JE, Fox NC, Rossor MN, Warren JD: Word-finding difficulty: a clinical analysis of the progressive aphasias. Brain 2008;131:8–38.
  31. Hodges JR: Alzheimer’s disease and the frontotemporal dementias: contributions to clinico-pathological studies, diagnosis and cognitive neuroscience. J Alzheimers Dis 2012, E-pub ahead of print.
  32. Mesulam MM, Wieneke C, Thompson C, Rogalski E, Weintraub S: Quantitative classification of primary progressive aphasia at early and mild impairment stages. Brain 2012;135:1537–1553.
  33. Sajjadi SA, Patterson K, Arnold RJ, Watson PC, Nestor PJ: Primary progressive aphasia: a tale of two syndromes and the rest. Neurology 2012;78:1670–1677.
  34. Mesulam M, Wieneke C, Rogalski E, Cobia D, Thompson C, Weintraub S: Quantitative template for subtyping primary progressive aphasia. Arch Neurol 2009;66:1545–1551.
  35. Josephs KA, Duffy JR, Strand EA, Machulda MM, Senjem ML, Master AV, Lowe VJ, Jack CR Jr, Whitwell JL: Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech. Brain 2012;135:1522–1536.
  36. Deramecourt V, Lebert F, Debachy B, Mackowiak-Cordoliani MA, Bombois S, Kerdraon O, Buée L, Maurage CA, Pasquier F: Prediction of pathology in primary progressive language and speech disorders. Neurology 2010;74:42–49.
  37. Yamamoto R, Iseki E, Higashi S, Murayama N, Minegishi M, Sato K, Hino H, Fujisawa K, Kosaka K, Togo T, Katsuse O, Uchikado H, Furukawa Y, Yoshida M, Hashizume Y, Arai H: Neuropathological investigation of regions responsible for semantic aphasia in frontotemporal lobar degeneration. Dement Geriatr Cogn Disord 2009;27:214–223.
  38. Nestor PJ, Balan K, Cheow HK, Fryer TD, Knibb JA, Xuereb JH, Hodges JR: Nuclear imaging can predict pathologic diagnosis in progressive nonfluent aphasia. Neurology 2007;68:238–239.
  39. Gorno-Tempini ML, Brambati SM, Ginex V, Ogar J, Dronkers NF, Marcone A, Perani D, Garibotto V, Cappa SF, Miller BL: The logopenic/phonological variant of primary progressive aphasia. Neurology 2008;71:1227–1234.
  40. Rohrer JD, Warren JD, Modat M, Ridgway GR, Douiri A, Rossor MN, Ourselin S, Fox NC: Patterns of cortical thinning in the language variants of frontotemporal lobar degeneration. Neurology 2009;72:1562–69.
  41. Rogalski E, Cobia D, Harrison TM, Wieneke C, Weintraub S, Mesulam MM: Progression of language impairments and cortical atrophy in subtypes of primary progressive aphasia. Neurology 2011;76:1804–1810.
  42. Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Otto M, Kornhuber J, Rüther E, Wiltfang J: Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias. Dement Geriatr Cogn Disord 2011;31:37–44.
  43. Goldman JS, Rademakers R, Huey ED, Boxer AL, Mayeux R, Miller BL, Boeve BF: An algorithm for genetic testing of frontotemporal lobar degeneration. Neurology 2011;76:475–483.
  44. Le Ber I, Camuzat A, Hannequin D, Pasquier F, Guedj E, Rovelet-Lecrux A, Hahn-Barma V, van der Zee J, Clot F, Bakchine S, Puel M, Ghanim M, Lacomblez L, Mikol J, Deramecourt V, Lejeune P, de la Sayette V, Belliard S, Vercelletto M, Meyrignac C, Van Broeckhoven C, Lambert JC, Verpillat P, Campion D, Habert MO, Dubois B, Brice A: Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain 2008;131:732–746.
  45. Van der Flier WM, Schooneboom SNM, Pijnenburg YAL, Fox NC, Scheltens P: The effect of APOE genotype on clinical phenotype in Alzheimer’s disease. Neurology 2006;67:526–527.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50